Novanta (NOVT) Q2 2026 earnings review
Massive Guidance Raise Driven by M&A, but Segment Margins Diverge
Novanta delivered a strong Q2 with GAAP revenue accelerating to 10.3% year-over-year growth ($266M) and Operating Cash Flow reversing its recent slump to hit a massive $64.9M. The headline story, however, is the transformative Riverpoint Medical acquisition. This deal immediately catalyzed a massive guidance hike, pushing expected Q3 revenue growth above 21% and FY26 revenue to a midpoint of $1,135M. Yet, beneath the headline beat, a stark divergence emerged: Automation margins surged 450 bps, while the core Medical Solutions segment—long touted as the high-margin growth engine—suffered a 290 bps margin contraction. The fundamental business is healthy, but the aggressive inorganic expansion masks some core integration and pricing friction.
🐂 Bull Case
Operating Cash Flow rocketed to $64.9M from $15.1M a year ago, proving the company can convert earnings efficiently. This liquidity fuels their aggressive M&A playbook, immediately validated by the Riverpoint deal.
The Automation Enabling Technologies (AET) segment continues to benefit from secular Physical AI and GenAI trends, driving a massive 450 bps YoY expansion in adjusted gross margin.
🐻 Bear Case
Despite management's aggressive pivot toward healthcare, the legacy Medical Solutions segment saw adjusted gross margin collapse from 44.0% to 41.1% YoY, indicating severe price/cost friction.
The massive leap in FY26 guidance is strictly due to the Riverpoint acquisition. Masking organic challenges with purchased revenue introduces heavy integration risk.
⚖️ Verdict: ⚪
Neutral/Bullish. The Riverpoint deal is strategically sound and financially accretive on paper, and the cash flow rebound is stellar. However, the troubling margin compression in the core Medical segment demands investor caution until organic pricing catches up to costs.
Key Themes
Riverpoint Medical Acquisition Alters Trajectory
Accelerating. The closure of the Riverpoint Medical acquisition is the dominant catalyst for the second half of 2026. Management notes it roughly doubles the recurring medical consumables business to ~25% of annualized sales and pushes total medical end-market exposure to ~60%. It is immediately accretive to margins and EPS, heavily driving the massive Q3 and FY26 guidance upgrades.
Medical Solutions Margin Collapse Contradicts Narrative
Reversing. For multiple quarters, management has framed the shift toward medical tech as a pure margin-accretive, defensive growth engine. Q2 data severely contradicts this. While Medical Solutions revenue grew 8.5% YoY, its Adjusted Gross Margin fell 290 basis points from 44.0% to 41.1%. This suggests the segment is struggling to pass through inflation and tariff costs to its healthcare OEM customers.
Automation segment (AET) Bails Out Profitability
Accelerating. The Automation Enabling Technologies (AET) segment was the unsung hero of Q2. Driven by prior investments in 'Physical AI' (warehouse robotics) and precision GenAI infrastructure (GPU board drilling), AET revenue grew 12% YoY. Crucially, its Adjusted Gross Margin surged 450 bps to 53.4%, effectively masking the profitability drag from the Medical segment.
Working Capital Normalization Sparks Cash Flow Inflection
Reversing. After quarters of depressed cash generation due to intentional inventory building (to mitigate trade risks) and dual-running costs for manufacturing facility moves, cash flow has violently inflected upward. Operating Cash Flow hit $64.9M in Q2 (vs $15.1M in the prior year), providing the exact liquidity needed to comfortably digest the Riverpoint acquisition.
Macro Trade Policy and Tariff Volatility
Stable. The macro backdrop of tariffs remains a persistent headwind. While the company executed plant closures and footprint regionalization to combat these dynamics, the margin compression in the Medical segment proves that 'price/cost timing impacts' mentioned in Q1 are still actively threatening bottom-line performance across certain product lines.
Integration Risk on Aggressive Capital Deployment
Accelerating. Novanta is relying heavily on M&A to meet its ambitious 2026 and 2030 targets. Bolting on Riverpoint Medical fundamentally alters the revenue base. While management has a decent integration track record (e.g., Kion), executing an acquisition that materially changes the Q3 guidance trajectory introduces immediate execution risk in a complex macro environment.
Other KPIs
Accelerating. Grew 16.4% YoY, outpacing the 10.3% GAAP revenue growth. This signals that despite the Medical segment's gross margin struggles, operating leverage and cost controls in SG&A, alongside AET's margin boom, successfully protected the bottom line. Adjusted EBITDA margin expanded to 22.8% from 21.6% a year ago.
Stable. The company continues to incur heavy non-GAAP adjustments for its strategic pivot. These costs remained flat YoY at ~$12.5M, reflecting ongoing expenses related to closing legacy facilities and executing the Riverpoint acquisition.
Guidance
Accelerating. The midpoint of $302M implies a massive 13.6% sequential jump from Q2 and >21% YoY growth. This aggressive acceleration is primarily driven by the inorganic injection of Riverpoint Medical revenues.
Accelerating. The midpoint of $75.5M represents a sharp sequential increase from Q2's $60.7M, further underscoring management's claim that the Riverpoint acquisition is immediately accretive to EBITDA margins.
Accelerating. Management completely overwrote their prior Q1 guidance of $1,040-$1,055M. The roughly $90M upward revision for the remainder of the year highlights the sheer scale of the Riverpoint integration relative to the legacy base business.
Accelerating. Lifted from the prior $3.50-$3.65 range. Represents >12% YoY growth. The upward revision confirms that the acquisition will overcome initial financing and integration costs to land accretively on the bottom line.
Key Questions
Medical Solutions Margin Disconnect
Adjusted gross margin in the Medical Solutions segment fell 290 bps year-over-year. Why is the pricing power failing to offset inflation in this specific segment, and what is the exact timeline for returning to margin expansion?
Organic vs. Inorganic Growth Rates
With the massive FY26 guidance hike clearly driven by Riverpoint Medical, what is the embedded organic growth expectation for the legacy business in the second half of 2026?
Riverpoint Integration Milestones
Given that Riverpoint doubles the recurring medical consumables business, what are the specific operational integration milestones over the next 12 months to secure the guided EBITDA accretion?